Trial Profile
Anlotinib in the Treatment of Recurrent High-grade Glioma an Open-label Single-arm, Phase 2 Trials
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Therapeutic Use
- 02 Jan 2024 Status changed from recruiting to completed.
- 02 Jan 2024 Results published in the BMC Cancer
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress